MRK vs SLB: Which Is the Better Buy?
Side-by-side comparison of Merck & Co., Inc. and SLB N.V. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
Merck & Co., Inc. · Healthcare
$121.42
-2.9% upside to fair value
Med Conviction
Grade B
VS
SLB N.V. · Energy
$51.92
-20.2% upside to fair value
Med Conviction
Grade C+
QuantHub Verdict
MRK has more upside to fair value
(-2.9%).
MRK trades at a lower forward P/E
(14.0x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MRK |
SLB |
| Current Price |
$121.42 |
$51.92 |
| Fair Value Estimate |
$118.00 |
$41.43 |
| Upside to Fair Value |
-2.9%
|
-20.2%
|
| Market Cap |
$300.2B |
$77.9B |
| Forward P/E |
14.0x
|
18.6x
|
| EV / EBITDA |
11.8x
|
9.2x
|
| Price / Sales |
4.1x
|
2.2x
|
| Price / FCF |
21.4x
|
16.1x
|
| Revenue Growth YoY |
+1.3%
|
-1.6%
|
| Gross Margin |
81.5%
|
18.21%
|
| Operating Margin |
41.2%
|
15.28%
|
| Return on Equity |
34.7%
|
12.83%
|
| Dividend Yield |
3.1% |
2.21% |
| FCF Yield |
4.7%
|
6.21%
|
| Analyst Consensus |
Buy
|
Buy
|
Investment Thesis
Merck is a top-5 global pharmaceutical company generating $65B in annual revenue with 81.5% gross margins and 28% net margins. Keytruda, the world's best-selling drug at $31.7B (49% of pharma revenue), faces patent expiry in 2028. Merck is aggressively building replacements through M&A and pipeline launches: Winrevair ($1.4B year one), Capvaxive ($759M), and the $6.7B Terns acquisition for TERN-7…
SLB is the world's largest oilfield services company with $35.7B in FY2025 revenue, operating across four divisions: Digital and Integration, Reservoir Performance, Well Construction, and Production Systems. The company completed the ChampionX acquisition in 2025 and is pursuing a digital transformation and AI-driven strategy. At $51.92, SLB trades at 2.18x P/S (in the fair range of the 5-year di…
Accumulation Zones
| Metric |
MRK |
SLB |
| Zone Low |
$88.00 |
$34.00 |
| Zone High |
$100.00 |
$39.00 |
| In Buy Zone? |
No
|
No
|